FDA approves Wegovy as anti-obesity medication for teens with once-weekly dosing.
December 23, 2022
Briumvi (ublituximab-xiiy) is approved for the treatment of relapsing forms ofmultiple sclerosis
December 28, 2022
December 27, 2022 - Acer Therapeutics Inc. and its collaboration partner, RELIEF THERAPEUTICS Holding SA, have announced that the U.S. Food and Drug Administration (FDA) has approved OlpruvaTM (sodium phenylbutyrate) for oral suspension in the U.S. for the treatment of certain patients living with urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).
Olpruva is used along with certain therapies, including changes in diet, for the long-term management of adults and children weighing 44 pounds (20 kg) or more. It is not used to treat a rapid increase of ammonia in the blood (acute hyperammonemia), which can be life-threatening and requires emergency medical treatment.